A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies

Completed · Phase 1

Conditions studied: Cancer

In brief

Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-04554878 in patients with advanced non-hematologic malignancies, including patients with malignancies appropriate for serial biopsy. Screening consists of medical history, physical examination ECOG performance status, blood draws, a pregnancy test for female patients of childbearing potential, a FDG-PET and tumor imaging. Treatment consists of PF-04554878 pills continued until progression of disease, unacceptable toxicity, or patient request. Evaluations for bioactivity are measured by serial FDG-PET and blood tests for biomarkers related to FAK and Pyk2 activities.

Key facts

Study ID: NCT00787033
Run by: Verastem, Inc.
People needed: 46
Starts: 2008-12-01
Expected to finish: 2012-02-01
Last updated by the study team: 2017-01-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with advanced non-hematologic malignancies.
Adequate organ function, including bilirubin less than 1.5 x ULN, and ECOG (Eastern Cooperative Oncology Group) performance status of 0-2.

You may not qualify if…

Clinically significant gastrointestinal abnormalities, requirement for systemic anticoagulants or potent CYP 2C8 inhibitors, and history of clinically significant cardiac or pulmonary disorders

Where it is running

Pfizer Investigational Site — Boston, Massachusetts, United States
Pfizer Investigational Site — Boston, Massachusetts, United States
Pfizer Investigational Site — Boston, Massachusetts, United States
Pfizer Investigational Site — Nashville, Tennessee, United States
Pfizer Investigational Site — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.